Retrospective · public company · facts checkable against public records. A diligence read of knowable, cited facts — not a forecast of outcomes.
A retrospective, high-level read on a public company — assembled the way a full Vantage report is: from primary public records, with factual claims cited to their sources. The numeric composite and per-domain confidence bands live in the full report; the qualitative read is below.
Shockwave Medical presents as a differentiated, FDA-authorized cardiovascular platform. Its core technology — Intravascular Lithotripsy (IVL), which uses sonic pressure waves to fracture arterial calcium — addresses two large, well-defined disease areas: calcified coronary artery disease and peripheral artery disease. Its regulatory record spans two distinct FDA routes: coronary IVL was FDA-approved via the PMA pathway in 2021 (PMA P200039 ↗), and peripheral IVL catheters are cleared via the 510(k) pathway, including the M5+ catheter in April 2021 (510(k) K203365 ↗). Its capital-markets history is fully public — an IPO on NASDAQ (ticker SWAV) in 2019 ↗ and, later, an acquisition by Johnson & Johnson for approximately $13.1 billion (announced April 2024) ↗. Each of those four facts links to its primary public record — click any of them.
A disciplined diligence read is not a cheerleader. Even on a company with this trajectory, the risks that genuinely existed along the way are worth naming: single lead-technology concentration, competitive response from large incumbents pursuing calcium-modification technology, and reimbursement uncertainty for a novel modality. Those are covered in Chapter 3 as risk considerations — qualitatively, and without invented numbers.
Every full Vantage report scores eight domains. This teaser shows a high-level qualitative read per domain with one grounded, publicly checkable sentence each. The Regulatory domain is shown most fully: its approval and clearance identifiers are cited and clickable to the FDA’s own device database, and a few Financial, Clinical, and IP facts link straight to their primary public records so you can verify them yourself. The numeric per-domain scores and confidence bands remain in the full report.
The point of a diligence read is that it flags real risks even on a strong company. These are stated qualitatively, from the knowable public picture — no invented numbers, no forecast of outcomes.
The business is anchored on one core technology — Intravascular Lithotripsy. Concentration on a single lead technology is a genuine consideration a diligence read surfaces, independent of how the technology ultimately performed.
Calcium modification is an area large, well-capitalized incumbents pursue. Competitive response from established players is a real consideration for any differentiated device platform addressing the same clinical problem.
A new mechanism does not arrive with settled coverage and coding. Reimbursement uncertainty is a standard, material consideration for a novel modality, and one a diligence read names explicitly rather than assumes away.
This is an abbreviated teaser, not a full report on this company. A full Vantage report includes cited sources, per-domain confidence bands and comparable companies.